Melanoma
Showing NaN - NaN of 82
Colorectal Carcinoma, Endometrial Carcinoma, Melanoma Trial in United States (Tegavivint)
Recruiting
- Colorectal Carcinoma
- +21 more
- Dual X-ray Absorptiometry
- +2 more
-
Birmingham, Alabama
- +18 more
Jan 30, 2023
Melanoma, NSCLC, Bladder Cancer Trial in Worldwide (Autogene cevumeran, Atezolizumab)
Active, not recruiting
- Melanoma
- +7 more
- Autogene cevumeran
- Atezolizumab
-
Scottsdale, Arizona
- +36 more
Dec 22, 2022
Melanoma, NSCLC, Colorectal Cancer Trial in United States (LYL845)
Recruiting
- Melanoma
- +2 more
- LYL845
-
Columbus, Ohio
- +3 more
Dec 19, 2022
Melanoma Trial in Worldwide (Dabrafenib, Trametinib, Placebos)
Melanoma Trial in Worldwide (Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination)
Recruiting
- Melanoma
- Nivolumab
- Nivolumab + Relatlimab Fixed Dose Combination
-
Birmingham, Alabama
- +185 more
Dec 3, 2022
Melanoma, Breast Carcinoma, Hepatocellular Carcinoma Trial in United States (XmAb20717)
Completed
- Melanoma
- +27 more
- XmAb20717
-
Los Angeles, California
- +16 more
Nov 29, 2022
Melanoma Trial in Worldwide (Talimogene Laherparepvec, Pembrolizumab, Placebo)
Terminated
- Melanoma
- Talimogene Laherparepvec
- +2 more
-
Birmingham, Alabama
- +160 more
Nov 10, 2022
Melanoma Trial in Worldwide (Pembrolizumab, Placebo)
Active, not recruiting
- Melanoma
- Pembrolizumab
- Placebo
-
Tucson, Arizona
- +158 more
Oct 31, 2022
Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,
Recruiting
- Advanced Malignant Solid Neoplasm
- +49 more
- Adavosertib
- +36 more
-
Birmingham, Alabama
- +1429 more
Aug 17, 2022
Melanoma, Solid Tumor Trial in Korea, Republic of, Spain, United States (DAY101, Pimasertib Hydrochloride)
Recruiting
- Melanoma
- Solid Tumor
- DAY101
- Pimasertib Hydrochloride
-
Los Angeles, California
- +13 more
Jul 27, 2022
Oncology, Solid Tumor, Non Small Cell Lung Cancer Trial in United States (MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution
Active, not recruiting
- Oncology
- +5 more
- MRx0518
- Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
-
Kansas City, Kansas
- +4 more
Jul 5, 2022
Oncology, Melanoma, Ovarian Cancer Trial in United States (E-602, Pembrolizumab)
Recruiting
- Oncology
- +16 more
- E-602
- Pembrolizumab
-
Grand Rapids, Michigan
- +4 more
May 27, 2022
Unresectable And Metastatic Melanoma: The Optimize Study
Completed
- Melanoma
-
Muscle Shoals, Alabama
- +65 more
May 17, 2022
Melanoma, Non Small Cell Lung Cancer Trial in United States (VV1, Cemiplimab, Ipilumumab)
Recruiting
- Melanoma
- Non Small Cell Lung Cancer
- VV1
- +2 more
-
Phoenix, Arizona
- +22 more
Apr 21, 2022
Melanoma Patients Treated With IMLYGIC® to Characterize Risk of
Recruiting
- Melanoma
- Herpetic Infection
-
Jefferson City, Missouri
- +16 more
Apr 11, 2022
Melanoma Trial in Pittsburgh (Zimberelimab, Domvanalimab)
Recruiting
- Melanoma
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Apr 11, 2022